RELIEF THERAPEUTICS Holding (RLF) AI Stock Analysis

• Market Cap: CHF37.21M
• Dividend Yield: N/A
• Average Volume (3M): 59.97K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.02
• Revenue Growth: -52.81%
• EPS Growth: 63.16%
• Country: CH
• Employees: 31
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.36
• Shares Outstanding: 14,092,317
• 10 Day Avg. Volume: 27,877
• 30 Day Avg. Volume: 59,967
• PEG Ratio: 0.04
• Price to Book (P/B): 1.44
• Price to Sales (P/S): 6.27
• P/FCF Ratio: -17.10
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.32
• Revenue Forecast (FY): CHF60.65M

• Rating: 44 Neutral
• Price Target: CHF3.00 ▲(14.07% Upside)

The overall stock score is primarily influenced by the company's financial performance, which shows potential but is hindered by ongoing losses and cash flow issues. Technical analysis provides a mixed outlook with some positive short-term trends, while valuation remains a concern due to negative earnings.

RELIEF THERAPEUTICS Holding Business Overview & Revenue Model

Company Description

RELIEF THERAPEUTICS Holding AG is a Swiss-based biopharmaceutical company focused on developing and commercializing novel, patent-protected products in the areas of rare metabolic and genetic disorders, as well as respiratory diseases. The company is committed to providing therapeutic relief and improving the quality of life for patients with serious medical conditions. RELIEF THERAPEUTICS operates in the healthcare and biotechnology sectors, leveraging its expertise in drug development and strategic partnerships to bring innovative treatments to market.

How the Company Makes Money

RELIEF THERAPEUTICS makes money through the development and commercialization of its proprietary drug candidates. The company's primary revenue streams include licensing agreements, royalties from partnered products, and sales of its own therapeutic products. By engaging in strategic collaborations and partnerships with other biopharmaceutical companies, RELIEF THERAPEUTICS can expand its reach and enhance its product pipeline, which in turn contributes to its revenue. Additionally, the company may receive milestone payments related to the development and commercialization progress of its partnered drugs. These financial structures enable RELIEF THERAPEUTICS to sustain its operations and invest in further research and development activities.

RELIEF THERAPEUTICS Holding Financial Statement Overview

Summary

RELIEF THERAPEUTICS Holding shows revenue growth and a strong equity position, but ongoing losses and negative free cash flow highlight profitability and cash management challenges. The company has potential for improvement but faces significant operational hurdles.

Income Statement

The company shows some improvement in revenue, with a 39.5% growth from the previous year. Gross profit margin improved to 69.4%, but net profit remains negative, impacting the overall profitability. EBIT and EBITDA margins are negative, indicating operational challenges and inefficiencies.

Balance Sheet

The debt-to-equity ratio is low at 0.06, suggesting limited leverage. However, the return on equity is negative due to continued net losses. The equity ratio is strong at 68.9%, indicating financial stability with a substantial equity base.

Cash Flow

Free cash flow remains negative, but it has improved compared to the previous year. The operating cash flow to net income ratio is less relevant due to negative net income. The company needs to improve cash generation to support operations and growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.05M	8.42M	6.03M	6.08M	3.32M	0.00
Gross Profit	-1.18M	5.84M	4.11M	4.83M	-8.59M	0.00
EBITDA	-18.22M	-16.73M	-108.04M	-50.26M	-32.69M	-6.09M
Net Income	-17.04M	-17.12M	-98.18M	-50.79M	-34.70M	-7.83M
Balance Sheet
Total Assets	47.99M	53.22M	76.39M	188.80M	251.62M	78.05M
Cash, Cash Equivalents and Short-Term Investments	12.50M	15.08M	14.56M	19.24M	44.76M	43.15M
Total Debt	1.90M	2.14M	2.96M	4.34M	4.26M	891.00K
Total Liabilities	15.35M	16.56M	24.16M	43.38M	70.09M	11.00M
Stockholders Equity	32.63M	36.66M	52.23M	145.42M	181.53M	67.04M
Cash Flow
Free Cash Flow	-3.43M	-3.09M	-18.06M	-24.63M	-49.42M	-18.23M
Operating Cash Flow	-3.40M	-2.92M	-17.61M	-24.11M	-35.71M	-18.23M
Investing Cash Flow	5.59M	4.40M	8.70M	-8.02M	-30.27M	3.00M
Financing Cash Flow	-303.00K	-862.00K	4.05M	6.42M	67.69M	58.18M

RELIEF THERAPEUTICS Holding Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.63
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:RLF, the sentiment is Neutral. The current price of 2.63 is below the 20-day moving average (MA) of 2.95, below the 50-day MA of 3.02, and below the 200-day MA of 2.68, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 48.30 is Neutral, neither overbought nor oversold. The STOCH value of 14.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CH:RLF.

RELIEF THERAPEUTICS Holding Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NWRN	74 Outperform	$285.44M	11.94	―	―	744.64%	―
BSLN	73 Outperform	CHF568.22M	7.80	―	―	58.51%	―
MOLN	55 Neutral	$129.20M	-1.97	-49.86%	―	-100.00%	14.45%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IDIA	45 Neutral	CHF790.83M	-4.75	―	―	228.54%	63.37%
RLF	44 Neutral	CHF37.21M	―	-40.91%	―	-52.81%	63.16%
SANN	41 Neutral	$140.58M	-2.05	-301.13%	―	-56.85%	-186.55%

RELIEF THERAPEUTICS Holding Corporate Events

Relief Therapeutics Plans Strategic Merger with NeuroX Group

Relief Therapeutics has announced an extraordinary general meeting to seek shareholder approval for a business combination with NeuroX Group SA. The meeting will address proposals including a capital increase and board member elections, aiming to rename the combined entity MindMaze Therapeutics Holding SA. This strategic move is expected to enhance Relief’s position in the biopharmaceutical industry by integrating NeuroX’s advanced neurotherapeutic technologies, potentially benefiting stakeholders through expanded treatment options and market reach.

The most recent analyst rating on (CH:RLF) stock is a Hold with a CHF2.50 price target. To see the full list of analyst forecasts on RELIEF THERAPEUTICS Holding stock, see the CH:RLF Stock Forecast page.

Relief Therapeutics and NeuroX Merge to Form AI-Driven Health Tech Leader

Relief Therapeutics and NeuroX have signed a definitive agreement to merge, creating a publicly listed AI-driven health tech company named MindMaze Therapeutics Holding SA. This merger positions the company as a leader in neurotherapeutic solutions, leveraging a robust commercialization network and a proprietary neuro-data engine for scalable precision medicine. The transaction, expected to close in December 2025, involves a significant equity exchange and aims to expand the company’s market presence and investor appeal, with plans to enhance visibility in the U.S. market.

The most recent analyst rating on (CH:RLF) stock is a Hold with a CHF3.00 price target. To see the full list of analyst forecasts on RELIEF THERAPEUTICS Holding stock, see the CH:RLF Stock Forecast page.

Relief Therapeutics Advances Pipeline and Explores AI-driven Expansion

Relief Therapeutics has released its 2025 half-year report, highlighting significant progress in its pipeline and corporate initiatives. The company has advanced its lead wound care candidate RLF-TD011 and is preparing for a pivotal trial of its next-generation liquid sapropterin formulation, RLF-OD032, for phenylketonuria. With cash reserves projected to last into late 2026, Relief is also exploring a business combination with NeuroX to establish an AI-driven health tech company.

Relief Therapeutics Advances 2025 Half-Year Report Publication

Relief Therapeutics has announced an advancement in the publication date of its 2025 half-year report, moving it forward to August 14, 2025, due to the early completion of the report. This report will include a shareholder update and interim financial statements, potentially impacting stakeholders by providing earlier insights into the company’s financial health and strategic direction.

Relief Therapeutics to Merge with NeuroX, Expanding AI-Driven Health Tech Platform

Relief Therapeutics has announced a proposed business combination with NeuroX, which recently acquired MindMaze, a leader in digital neurotherapeutics. This merger aims to create a publicly listed, AI-driven health tech company that integrates digital and pharmacological treatments for neurological diseases. The transaction is expected to close in Q4 2025, subject to customary conditions and approvals, and is anticipated to significantly enhance Relief’s market presence and growth potential.